Commure expands without equity dilution

The key point is that Commure found a way to fund rollout into more hospitals without issuing more common startup equity. General Catalyst’s $200M Customer Value Fund deal gave Commure expansion capital tied to scaling its AI powered revenue cycle and workflow products, so the company could add implementations, sales capacity, and product coverage while largely preserving ownership for existing shareholders and keeping its equity valuation intact ahead of the later $70M round at $7B.1 2 4

• Commure sells into hospitals on long, fixed fee software contracts, where growth often comes from landing one product, then adding adjacent modules like billing, patient communication, monitoring, or AI scribes. That makes financing for go live costs and customer expansion especially valuable, because the spend comes before the full contract value is realized.2 4
• By 2024, Commure had built a broad hospital stack through the Athelas merger and acquisitions, reaching about $105M ARR in March 2024. That breadth matters here, because non dilutive growth capital is most useful when a company already has multiple products it can cross sell into the same health system account.2 4
• This financing structure fits a wider General Catalyst pattern. Grammarly used Customer Value Fund financing in May 2025 to preserve its prior $13B equity valuation, and Chainguard later used the same fund at its existing $3.5B valuation. In practice, CVF functions like growth capital for companies that want more operating firepower without resetting ownership through a large priced equity round.5 6 7

The next step is likely more bundle expansion inside existing health systems, and more use of structured capital to pull forward that rollout. For Commure, the strategic win is not just cheaper capital, it is the ability to compound distribution across a bigger hospital software suite before eventual public market scrutiny forces cleaner margins and steadier growth.2 4